open access

Vol 52, No 3 (2021)
Review article
Submitted: 2021-05-23
Accepted: 2021-05-23
Get Citation

Current status and achievements of Polish transfusion medicine

Jolanta Antoniewicz-Papis1, Ewa Brojer2, Jadwiga Fabijańska-Mitek3, Agnieszka Gierszon2, Piotr Grabarczyk4, Katarzyna Guz2, Aleksandra Kalińska4, Aneta Kopacz4, Jolanta Korsak5, Elżbieta Lachert1, Magdalena Łętowska1, Patrycja Łopacz2, Bogumiła Michalewska2, Agata Mikołowska1, Jacek Nowak6, Adam Olszewski7, Agnieszka Orzińska2, Monika Pelc-Kłopotowska2, Ryszard Pogłód1, Piotr Radziwon8, Aleksandra Rosiek1, Anna Stachurska-Skrodzka3, Ewa Sulkowska4, Zbigniew M. Szczepiorkowski19, Małgorzata Uhrynowska2, Beata Uszyńska-Kałuża10, Beata Wojciechowska2
DOI: 10.5603/AHP.2021.0031
·
Acta Haematol Pol 2021;52(3):147-162.
Affiliations
  1. Department of Transfusion Medicine, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
  2. Department of Immunohematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
  3. Centre of Postgraduate Medical Education, Warsaw, Poland
  4. Department of Virology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
  5. Department of Transfusion Medicine, Military Institute of Medicine, Warsaw, Poland
  6. Department of Immunogenetics, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
  7. Military Blood Transfusion Center, Warsaw, Poland
  8. Regional Blood Transfusion Center, Białystok, Poland, Department of Hematology, Medical University of Białystok, Poland
  9. Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA
  10. Blood Transfusion Center of Ministry of Internal Affairs and Administration, Warsaw, Poland

open access

Vol 52, No 3 (2021)
REVIEW ARTICLE
Submitted: 2021-05-23
Accepted: 2021-05-23

Abstract

Transfusion of blood and blood components is one of the widely used medical procedures. The responsibility for provision of blood and blood components lies with Polish blood transfusion centers (CKiK) substantively supervised by the Institute of Hematology and Transfusion Medicine. Hospital based blood banks, hospital wards, immunohematology laboratories are supervised by CKiK. Every year approximately 600 thousand people donate blood, more than 75% of which are regular donors. The annual number of donations is maintained at a constant level of about 1.3 million.

The aim of this position paper is to present the current status, achievements and advancement in collection, preparation and testing procedures and methods used to obtain the best possible quality blood components dedicated for clinical use. The aim is also to show the structure of blood transfusion service in Poland. Collaboration of all organizational units involved in transfusion medicine is crucial for providing high quality health care for patients.

Polish transfusiologists and blood transfusion officers have largely contributed to transfusion science with numerous publications and significant research work. The implementation of novel methods and ongoing research positions Polish blood transfusion service among those of highly developed countries.

Abstract

Transfusion of blood and blood components is one of the widely used medical procedures. The responsibility for provision of blood and blood components lies with Polish blood transfusion centers (CKiK) substantively supervised by the Institute of Hematology and Transfusion Medicine. Hospital based blood banks, hospital wards, immunohematology laboratories are supervised by CKiK. Every year approximately 600 thousand people donate blood, more than 75% of which are regular donors. The annual number of donations is maintained at a constant level of about 1.3 million.

The aim of this position paper is to present the current status, achievements and advancement in collection, preparation and testing procedures and methods used to obtain the best possible quality blood components dedicated for clinical use. The aim is also to show the structure of blood transfusion service in Poland. Collaboration of all organizational units involved in transfusion medicine is crucial for providing high quality health care for patients.

Polish transfusiologists and blood transfusion officers have largely contributed to transfusion science with numerous publications and significant research work. The implementation of novel methods and ongoing research positions Polish blood transfusion service among those of highly developed countries.

Get Citation

Keywords

Transfusion Section of Polish Society of Hematologists and Transfusiologists, transfusion medicine

About this article
Title

Current status and achievements of Polish transfusion medicine

Journal

Acta Haematologica Polonica

Issue

Vol 52, No 3 (2021)

Article type

Review article

Pages

147-162

DOI

10.5603/AHP.2021.0031

Bibliographic record

Acta Haematol Pol 2021;52(3):147-162.

Keywords

Transfusion Section of Polish Society of Hematologists and Transfusiologists
transfusion medicine

Authors

Jolanta Antoniewicz-Papis
Ewa Brojer
Jadwiga Fabijańska-Mitek
Agnieszka Gierszon
Piotr Grabarczyk
Katarzyna Guz
Aleksandra Kalińska
Aneta Kopacz
Jolanta Korsak
Elżbieta Lachert
Magdalena Łętowska
Patrycja Łopacz
Bogumiła Michalewska
Agata Mikołowska
Jacek Nowak
Adam Olszewski
Agnieszka Orzińska
Monika Pelc-Kłopotowska
Ryszard Pogłód
Piotr Radziwon
Aleksandra Rosiek
Anna Stachurska-Skrodzka
Ewa Sulkowska
Zbigniew M. Szczepiorkowski
Małgorzata Uhrynowska
Beata Uszyńska-Kałuża
Beata Wojciechowska

References (90)
  1. Ustawa o publicznej służbie krwi. https://lexlege.pl/ustawa-o-publicznej-sluzbie-krwi/ (April 9, 2021).
  2. Directive 2002/98/EC of the European Parliament and of the Council of 27 January 2003setting standards of quality and safety for the collection, testing, processing, storage and distribution of human blood and blood components and amending Directive 2001/83/EC. OJ L 33, 8.2.2003, p. 30–40.
  3. Żak A, Lachert E, Antoniewicz-Papis J, et al. Ocena jakości ubogoleukocytarnych koncentratów krwinek czerwonych zamrażanych i rozmrażanych w systemie ACP 215. J Transf Med. 2011; 1: 32–43.
  4. Olszewski A, Korzeniewski K, Lass A. Selected epidemiological aspects of fresh whole blood application in the Polish Field Hospital in Afghanistan. Int Marit Health. 2014; 65(1): 23–27.
  5. Olszewski A, Machała W. Chodzący bank krwi w wojskowym szpitalu polowym w Afganistanie. Lek Wojsk. 2014; 92(1): 65–71.
  6. Ustawa z dnia 6 listopada 2008 r. o konsultantach w ochronie zdrowia (Dz.U. 2009 nr 52 poz. 419). https://isap.sejm.gov.pl/isap.nsf/DocDetails.xsp?id=WDU20090520419 (April 9, 2021).
  7. Heier HE, Badloe J, Bohonek M, et al. Use of tranexamic acid in bleeding combat casualties. Mil Med. 2015; 180(8): 844–846.
  8. NATO Medical Blood Advisory Team (MBAT). Position statement. The use of tranexamic (TXA) in bleeding combat. Draft 3 (Nov 29, 2011).
  9. Antoniewicz-Papis J. Informatyzacja publicznej służby krwi jako element zarządzania ryzykiem w krwiodawstwie i krwiolecznictwie. Instytut Hematologii i Transfuzjologii, Warszawa 2016.
  10. Projekt e-Krew. https://cez.gov.pl/projekty/realizowane/projekt-e-krew (April 9, 2021).
  11. Pelc-Kłopotowska M, Michalik M, Łopieńska H, et al. Polish External Quality Assessment Scheme for Blood Transfusion Laboratories: 5-year experience in conducting the program. Vox Sang. 2015; 109(Suppl 1): 266.
  12. Daniels G, van der Schoot CE, Olsson ML. Report of the fourth International Workshop on molecular blood group genotyping. Vox Sang. 2011; 101(4): 327–332.
  13. Clausen FB, Barrett AN. Noninvasive Fetal RHD Genotyping EQA2017 Working Group. Noninvasive fetal RHD genotyping to guide targeted anti-D prophylaxis-an external quality assessment workshop. Vox Sang. 2019; 114: 386–393.
  14. Lucas GF, Carrington PA. Results of the First International Granulocyte Serology Workshop. Vox Sang. 1990; 59(4): 251–256.
  15. Metcalfe P, Waters AH. Report on the fourth ISBT/ICSH platelet serology workshop (London 1988). Vox Sang. 1990; 58(2): 170–175.
  16. Guz K, Łopacz P, Gierszon A, et al. Ocena dostępności dawców koncentratów krwinek płytkowych o oznaczonych antygenach leukocytarnych i płytkowych dla pacjentów z przeciwciałami anty-HLA i/lub anty-HPA. J Transfus Med. 2019; 12(1): 1–12.
  17. Obwieszczenie Ministra Zdrowia z dnia 30 marca 2021 r. w sprawie wymagań dobrej praktyki pobierania krwi i jej składników, badania, preparatyki, przechowywania, wydawania i transportu dla jednostek organizacyjnych publicznej służby krwi (Dz. U. MZ, poz. 28, 2021). http://www.dziennikmz.mz.gov.pl/DUM_MZ/2021/28/oryginal/akt.pdf (April 9, 2021).
  18. Commission Directive 2005/61/EC of 30 September 2005 implementing Directive 2002/98/EC of the European Parliament and of the Council as regards traceability requirements and notification of serious adverse reactions and events. OJ L 256, 1.10.2005, p. 32–40.
  19. Antoniewicz-Papis J. Nowoczesne metody pobierania i preparatyki krwi i jej składników. Laboratorium. 2006; 5: 48–51.
  20. Rosiek A, Tomaszewska A, Lachert E, et al. Działalność jednostek organizacyjnych służby krwi w Polsce w 2018 roku. J Transf Med. 2019; 12: 127–143.
  21. Rosiek A, Tomaszewska A, Lachert E, et al. Blood transfusion service in Poland in 2018. J Transf Med. 2019; 12(4): 144–159.
  22. Antoniewicz-Papis J. Ubogoleukocytarne składniki krwi — otrzymywanie i zastosowanie. Laboratorium. 2007; 11: 24–27.
  23. Krwiodawstwo zbiór przepisów dla placówek służby krwi. ed. Sabliński J Łętowska M. Ministerstwo Zdrowia i Opieki Społecznej, Instytut Hematologii i Transfuzjologii, Warszawa 1996.
  24. Lachert E, Woźniak J, Antoniewicz-Papis J, et al. Study of CD69 antigen expression and integrity of leukocyte cellular membrane in stored platelet concentrates following irradiation and treatment with Mirasol® PRT System. Adv Clin Exp Med. 2017; 26(1): 7–13.
  25. Lachert E, Kubis J, Antoniewicz-Papis J, et al. Quality control of riboflavin-treated platelet concentrates using Mirasol® PRT system: Polish experience. Adv Clin Exp Med. 2018; 27(6): 765–772.
  26. Lachert E, Antoniewicz-Papis J, Kubis J, et al. et al.. PRT Mirasol System — validation experience in Poland. J Transf Med. 2012; 5: 91–93.
  27. Daszyński J, Maj S. Wpływ niskich temperatur na własności krwinek czerwonych. Pol Arch Med Wew. 1967; 39: 601–606.
  28. Kotelba-Witkowska B, Skrzeczkowska E, Mrowiec Z. Przechowywanie koncentratów krwinek płytkowych w temperaturze –80°C. Ocena in vitro. Acta Haematol Pol. 1984; 15: 27–33.
  29. Mrowiec Z, Skrzeczkowska E, Kotelba-Witkowska B, et al. Przechowywanie koncentratów krwinek płytkowych w temperaturze –80°C. Ocena in vivo. Acta Haematol Pol. 1986; 17: 9–16.
  30. Antoniewicz-Papis J, Lachert E, Rosiek A, et al. Otrzymywanie metodą automatyczną zlewanych koncentratów krwinek płytkowych. J Transf Med. 2010; 3: 49–54.
  31. Rozporządzenie Ministra Zdrowia z dnia 11 września 2017 r. w sprawie warunków pobierania krwi od kandydatów na dawców krwi i dawców krwi (Dz.U. 2017 poz. 1741). http://isap.sejm.gov.pl/isap.nsf/DocDetails.xsp?id=WDU20170001741 (April 9, 2021).
  32. Guide to the preparation, use and quality assurance of blood components. Recommendation No. R (95) 15. 20th Edition. European Directorate for the Quality of Medicines & HealthCare (EDQM), Strasbourg 2020.
  33. Sulkowska E, Kopacz A, Kubicka-Russel D, et al. Zastosowanie testu Syphilis Total Ab na aparacie Evolis (firmy BIO-RAD) do prowadzenia badań przeglądowych w krwiodawstwie. J Transf Med. 2017; 10(1): 1–11.
  34. Grabarczyk P, Koppelman M, Boland F, et al. Inclusion of human immunodeficiency virus type 2 (HIV-2) in a multiplex transcription-mediated amplification assay does not affect detection of HIV-1 and hepatitis B and C virus genotypes: a multicenter performance evaluation study. Transfusion. 2015; 55(9): 2246–2255.
  35. Kopacz A, Kubicka-Russel D, Liszewski G, et al. Charakterystyka testu cobas® MPX wraz z analizatorem cobas® 6800 oraz aparatem cobas p 680 (Roche) przeznaczonych do automatycznego badania dawców krwi w kierunku RNA wirusa zapalenia wątroby typu C (HCV), RNA ludzkiego wirusa nabytego niedoboru odporności (HIV) i DNA wirusa zapalenia wątroby typu B (HBV). J Transf Med. 2018; 11(2): 39–51.
  36. Sulkowska E, Kubicka-Russel D, Zwolińska P, et al. And Polish Working Group On TTI. Hepatitis A virus in blood donations — epidemiology, virological characteristics and transfusion transmitted infections during epidemic; Poland, 2017–2019. Vox Sang. 2020; 115(Suppl. S1): P–431.
  37. Grabarczyk P, Sulkowska E, Gdowska J, et al. Molecular and serological infection marker screening in blood donors indicates high endemicity of hepatitis E virus in Poland. Transfusion. 2018; 58(5): 1245–1253.
  38. Grabarczyk P. Transfusion-transmitted infections in Poland — trends, threats and prevention. Transfus Med Hemother. 2020; 47(Suppl 1): VS-13-1.
  39. Sulkowska E, Kubicka-Russel D, Chrzanowska A, et al. HIV infection in Polish blood donors from 2005 to 2018 — trends in epidemiology and residual transfusion transmission risk. Vox Sang. 2020; 115(Suppl. S1): P-399.
  40. Rozporządzenie Ministra Zdrowia w sprawie określenia rzadkich grup krwi, rodzajów osocza i surowic diagnostycznych, których uzyskanie wymaga przed pobraniem krwi lub jej składników wykonania zabiegu uodpornienia dawcy lub innych zabiegów, oraz wysokości rekompensaty (Dz. U. 2017, poz. 235). https://isap.sejm.gov.pl/isap.nsf/DocDetails.xsp?id=WDU20170000235 (April 9, 2021).
  41. Guz K, Orzińska A, Michalewska B, et al. Molecular biology methods for blood cell antigen genotyping in reference laboratories. J Transfus Med. 2019; 12(4): 199–205.
  42. Orzińska A, Guz K, Michalewska B, et al. Molecular screening of the C antigen for typing donors compatible with patients with anti-MAR-like antibodies. Blood Transfus. 2016; 14(6): 573–576.
  43. Guz K, Orzińska A, Pelc-Kłopotowska M, et al. Identification of blood donors with rare red blood cell phenotypes using low-cost protocols. Vox Sang. 2018; 113(Suppl. 1): 263.
  44. Obwieszczenie Ministra Zdrowia z dnia 17 lutego 2021 r. w sprawie ogłoszenia jednolitego tekstu rozporządzenia Ministra Zdrowia w sprawie leczenia krwią i jej składnikami w podmiotach leczniczych wykonujących działalność leczniczą w rodzaju stacjonarne i całodobowe świadczenia zdrowotne (Dz.U. 2021 poz. 504). http://isap.sejm.gov.pl/isap.nsf/DocDetails.xsp?id=WDU20210000504 (April 9, 2021).
  45. Obwieszczenie Ministra Zdrowia z dnia 18 marca 2020 r. w sprawie wymagań dobrej praktyki przechowywania i wydawania krwi i jej składników dla banków krwi oraz badań z zakresu immunologii transfuzjologicznej wykonywanych w zakładach leczniczych podmiotów leczniczych innych niż regionalne centra, Wojskowe Centrum lub Centrum MSWiA (Dz.U. MZ. poz. 25, 2020). http://dziennikmz.mz.gov.pl/DUM_MZ/2020/25/akt.pdf (April 9, 2021).
  46. Michalewska B, Wojciechowska B, Bednarz J, et al. Ocena funkcjonowania Pracowni Immunologii Transfuzjologicznej w Polsce. Acta Haematol Pol. 2017; 40(Suppl 1): 118.
  47. Bednarz J, Pelc-Kłopotowska M, Wojciechowska B, et al. Assessment of the activities of Polish hospital transfusion laboratories based on surveys performed in 2015 and 2018. Vox Sang. 2020; 115(Suppl 1): 78.
  48. Pelc-Kłopotowska M, Wojciechowska B, Bednarz J, Sierpińska M, Guz K, Orzińska A, Michalewska B, Brojer E. Badania przedtransfuzyjne u pacjentów leczonych daratumumabem przy użyciu krwinek traktowanych DTT i DaraEx. Zeszyt Streszczeń XXVIII Zjazd Polskiego Towarzystwa Hematologów i Transfuzjologów Łódź, 12–14.09.2019.
  49. Michalewska B, Żupańska B, Pelc-Kłopotowska M, et al. Alloimmunization in patients with autoimmune haemolytic anemia and genotyping of red blood cells to improve the selection of blood for transfusion]. J Transfus Med. 2009; 1: 14–19.
  50. Pelc-Kłopotowska M, Guz K, Orzińska A, et al. Antibodies against high frequency antigen detected in patients between 2000 and 2017. Vox Sang. 2018; 113(Suppl. 1): 231.
  51. Zupańska B, Brojer E, Richards Y, et al. Serological and immunological characteristics of maternal anti-Rh(D) antibodies in predicting the severity of haemolytic disease of the newborn. Vox Sang. 1989; 56(4): 247–253.
  52. Żupańska B, Nowaczek-Migas M, Michalik M, et al. Whether all pregnant women should be screened for antibodies other than anti-D?]. Gin po Dypl. 2009; 2: 38–40.
  53. Uhrynowska M, Niznikowska-Marks M, Zupańska B. Neonatal and maternal thrombocytopenia: incidence and immune background. Eur J Haematol. 2000; 64(1): 42–46.
  54. Dębska M, Uhrynowska M, Guz K, et al. Identification and follow-up of pregnant women with platelet-type human platelet antigen (HPA)-1bb alloimmunized with fetal HPA-1a. Arch Med Sci. 2018; 14(5): 1041–1047.
  55. Uhrynowska M, Guz K, Orzińska A, et al. Results of HPA-1a screening program for identification of pregnant women at risk of foetal/neonatal alloimmune thrombocytopenia (FNAIT). Vox Sang. 2019; 114(Suppl.1): 59.
  56. Orzińska A, Guz K, Uhrynowska M, et al. Noninvasive prenatal HPA-1 typing in HPA-1a negative pregnancies selected in the Polish PREVFNAIT screening program. Transfusion. 2018; 58(11): 2705–2711.
  57. Kotelba-Witkowska B, Zupańska B, Brojer E, et al. Predictive value of lymphocytotoxic test and platelet aggregometry for the effect of transfused platelet concentrates. Haematologia (Budap). 1981; 14(4): 375–381.
  58. Maślanka K, Guz K, Uhrynowska M, et al. [Registry of blood donors typed for human platelet antigens (HPA) and its application in platelet transfusion]. Acta Haematol Pol. 2005; 36: 189–196.
  59. Guz K, Łopacz P, Gierszon A, et al. Availability of the platelet concentrates for immunized patients from donors with HLA and/or HPA typed antigens. J Transfus Med. 2019; 12: 1–12.
  60. Zupańska B, Uhrynowska M, Konopka L. Transfusion-related acute lung injury due to granulocyte-agglutinating antibody in a patient with paroxysmal nocturnal hemoglobinuria. Transfusion. 1999; 39(9): 944–947.
  61. Maślanka K, Michur H, Zupańska B, et al. Leucocyte antibodies in blood donors and a look back on recipients of their blood components. Vox Sang. 2007; 92(3): 247–249.
  62. Maślanka K, Uhrynowska M, Łopacz P, et al. Analysis of leucocyte antibodies, cytokines, lysophospholipids and cell microparticles in blood components implicated in post-transfusion reactions with dyspnoea. Vox Sang. 2015; 108(1): 27–36.
  63. TRALI i prawdopodobne TRALI zdiagnozowane w Polsce w okresie styczeń 2014 — marzec 2019; analiza wyników badań laboratoryjnych. Zeszyt Streszczeń, str 50. XXVIII Zjazd Polskiego Towarzystwa Hematologów i Transfuzjologów. Łódź, 12–14.09.2019.
  64. Drzewek K, Brojer E, Zupańska B. The frequency of human platelet antigen (HPA) genotypes in the Polish population. Transfus Med. 1998; 8(4): 339–342.
  65. Guz K, Brojer E, Zupańska B. Implications of NA1/NA2 and SH genotyping results in the Polish population with regard to the new nomenclature of granulocyte alloantigens. Transfusion. 2000; 40(4): 490–1; author reply 492.
  66. Orzińska A, Guz K, Polin H, et al. RHD variants in Polish blood donors routinely typed as D-. Transfusion. 2013; 53(11 Suppl 2): 2945–2953.
  67. Pelc-Kłopotowska M, Guz K, Orzińska A, et al. Evaluation of reactivity of various monoclonal anti-D reagents with red blood cells of individuals with inconclusive RhD results. Vox Sang. 2020; 115(Suppl.1): 256.
  68. Michalewska B, Olsson ML, Naremska G, et al. FUT1 mutations responsible for the H-deficient phenotype in the Polish population, including the first example of an abolished start codon. Blood Transfus. 2018; 16(1): 101–104.
  69. Polin H, Pelc-Klopotowska M, Danzer M, et al. Compound heterozygosity of two novel RHAG alleles leads to a considerable disruption of the Rh complex. Transfusion. 2016; 56(4): 950–955.
  70. Guz K, Pelc-Kłopotowska M, Purchla-Szepioła S, et al. A novel ABO*A allele with 21 base pair duplication in Polish individuals. Transfusion. 2020; 60(11): E48–E50.
  71. Orzińska A, Guz K, Dębska M, et al. 14 years of Polish experience in non-invasive prenatal blood group diagnosis. Transfus Med Hemother. 2015; 42(6): 361–364.
  72. Orzińska A, Guz K, Purchla-Szepioła S, et al. 3-year experimenst in non-invasive prenatal testing of fetal RHD for targeted anti-D immunoprophylaxis in Poland. Vox Sang. 2019; 114(Suppl 1): 201.
  73. Orzińska A, Guz K, Mikula M, et al. Prediction of fetal blood group and platelet antigens from maternal plasma using next-generation sequencing. Transfusion. 2019; 59(3): 1102–1107.
  74. Stachurska A, Król T, Trybus W, et al. 3D visualization and quantitative analysis of human erythrocyte phagocytosis. Cell Biol Int. 2016; 40(11): 1195–1203.
  75. Fabijańska-Mitek J, Stachurska A. Zastosowanie cytometrii przepływowej w badaniach immunohematologicznych krwinek czerwonych. Acta Haematol Pol. 2017; 48(3): 183–188.
  76. Stachurska A, Dorman M, Korsak J, et al. Selected CD molecules and the phagocytosis of microvesicles released from erythrocytes ex vivo. Vox Sang. 2019; 114(6): 576–587.
  77. Lachert E, Antoniewicz–Papis J, Kubis J, et al. Klej fibrynowy. Blok operacyjny. 2002; 2: 80–83.
  78. Antoniewicz-Papis J, Lachert E, Janik K, et al. Autologous artificial tears used for treatment of dry eye syndrome in patients with chronic graft versus host disease. Pol Arch Intern Med. 2017; 127(10): 705–707.
  79. Wunsch E, Kruk B, Snarski E, et al. Plasmapheresis in the treatment of chronic fatigue in patients with primary biliary cholangitis. Pol Arch Intern Med. 2021; 131(2): 205–207.
  80. Padmanabhan A, Connelly-Smith L, Aqui N, et al. Guidelines on the use of therapeutic apheresis in clinical practice — evidence-based approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J Clin Apher. 2019; 34(3): 171–354.
  81. Nowak J, Gronkowska A, Brojer E. Strategy of marrow donor search among family members for the patients who do not have a matched sibling. Acta Haematol Pol. 2002; 33: 309–316.
  82. Nowak J. Matching and recruitment of unrelated bone marrow donors in Poland. Acta Haematol Pol. 2002; 33: 417–430.
  83. Nestorowicz K, Łęczycka A, Dudkiewicz M. Centralny Rejestr Niespokrewnionych Potencjalnych Dawców Szpiku i Krwi Pępowinowej (CRNPDSiKP). Poltransplant Biuletyn Informacyjny. 2020; 29: 61–69.
  84. Nowak J, Nestorowicz K, Graczyk-Pol E, et al. HLA-inferred extended haplotype disparity level is more relevant than the level of HLA mismatch alone for the patients survival and GvHD in T cell-replate hematopoietic stem cell transplantation from unrelated donor. Hum Immunol. 2018; 79(6): 403–412.
  85. Graczyk-Pol E, Rogatko-Koros M, Nestorowicz K, et al. Role of donor HLA class I mismatch, KIR-ligand mismatch and HLA:KIR pairings in hematological malignancy relapse after unrelated hematopoietic stem cell transplantation. HLA. 2018; 92 Suppl 2: 42–46.
  86. Nowak J, Kościńska K, Mika-Witkowska R, et al. Polish Donor-Recipient Matching Study Group. Donor NK cell licensing in control of malignancy in hematopoietic stem cell transplant recipients. Am J Hematol. 2014; 89(10): E176–E183.
  87. Poszwiński P, Węgrzecki T, Seyfried H, et al. Produkcja immunoglobuliny anty-D. Pol Tyg Lek. 1974; 29: 823–825.
  88. Seyfried H, Poszwiński P, Frankowska K, et al. Czteroletnie doświadczenie w dziedzinie produkcji i stosowania immunoglobuliny anty RhD. 1. Produkcja preparatów gamma anty-D. Ginekol Pol. 1978; 49: 743–746.
  89. Poszwiński P, Kacperska E, Głoskowska-Moraczewska Z, et al. Immunoglobulina anty-HBs. Pol Tyg Lek. 1979; 34(46): 1789–1791.
  90. Standard Pracy Komitetu Transfuzjologicznego. ed. Pogłód R, Antoniewicz-Papis J. Wydanie II. Instytut Hematologii i Transfuzjologii, Warszawa 2020.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl